encapsulated within liposomes) into the capsule.

ENCAPSULATING ENTERAL OR ENETRIC COATING AND GELATIN

013333780
WPI Acc No: 2000-505719/200045
Particle for oral administration of biopolymeric drugs, e.g. proteins or nucleic acids, comprises active ingredient in a substrate and a coating of mucoadhesive for attachment to intestinal mucosa
Patent Assignee: IMEDD (IMED-N); UNIV CALIFORNIA (REGC)
Inventor: DEHLINGER P J; FERRARI M; FRIEND D R; GROVE C F; MARTIN F J
Number of Countries: 021 Number of Patents: 002
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 200041740	A2	20000720	WO 2000US362	A	20000107	200045 B
AU 200024947	A	20000801	AU 200024947	A	20000107	200054

Priority Applications (No Type Date): US 99115424 A 19990111; US 99115420 A 19990111
Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
WO 200041740	A2	E	48	A61M-000/00	
AU 200024947	A			A61M-000/00	Based on patent WO 200041740

Designated States (National): AU CA JP
Designated States (Regional): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

Abstract (Basic): WO 200041740 A2

NOVELTY - Particle (A) for oral delivery of a biopolymeric drug (I) (e.g. polypeptide, protein or nucleic acid), comprising a substrate having at least 1 reservoir containing (I) in releasable form and opening to 1 face of the substrate, which is coated with a mucoadhesive agent (II) for the attachment of (A) to the intestinal mucosa so that (I) is released directly into the lining, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) an oral composition containing many (A); and

(2) a microfabrication method comprising exposing a sheet of particle-forming material to a photoablative light source through a mask, so that a network pattern corresponding to the required shape and size of (A) is produced, and continuing exposure until (A) are formed.

USE - (A) are used for the oral delivery of (I) to the intestines, e.g., the delivery of erythropoietin (for treating anemia), interferons (hepatitis), interleukins (cancer), insulin (diabetes mellitus), calcitonin (osteoporosis) and antisense oligonucleotides (cancer, infections, inflammation).

ADVANTAGE - (II) ensure attachment to the intestines and their shape, size, density and composition can be adjusted to control contact with the gut wall. (A) are too large to undergo endocytosis by gut epithelial cells and they can be labeled for detection or visualization. They may also include penetration enhancers; protease inhibitors or agents that control release rate of (I), to improve bioavailability.

pp; 48 DwgNo 0/8

Derwent Class: A96; B04; B05; B07; D16; P34
International Patent Class (Main): A61M-000/00